Scientists have developed an AI-assisted prediction tool that can identify patients with type 2 diabetes at high risk of developing diabetic retinal neurodegeneration (DRN) before symptoms appear. Their findings were published today in the journal PLOS Medicine.
“Our study suggests that early retinal nerve damage in diabetes leaves measurable signals in the blood,” write the authors of the study, led by Wei Wang, MD, PhD, associate professor at the Guangdong Provincial Clinical Research Center for Ocular Diseases. “These findings suggest that a simple blood test analyzed with artificial intelligence may help identify people with diabetes who are at highest risk of early retinal nerve damage, well before visible damage appears on the retina.”
Type 2 diabetes affects more than half a billion people worldwide, carrying with it an increased risk of long-term complications including progressive neurodegeneration. Retinal nerves are among the earliest tissues to be damaged, which can eventually lead to severe visual impairment and vision loss. However, current diagnostic methods can only detect DRN once the retina has already suffered irreversible damage.
Wang and colleagues developed a machine learning algorithm called Pro-DRN using data from 1,218 participants in the Guangzhou Diabetic Eye Study, all of whom were diagnosed with type 2 diabetes but had not yet developed DRN at the time of enrollment. The AI model integrated proteomics data from blood samples with yearly retinal images collected over a six-year follow-up period.
This led to the identification of 71 proteins associated with the development of DRN. Among them, the proteins most consistently driving accurate predictions were ACTA2, COL6A3, and HSPG2, which are key structural components involved in maintaining the integrity of the nerve and muscle tissue in the eyes. These results were then validated in an independent cohort of 502 patients from UK Biobank, where the core effects and protein signals were reproduced.
Pro-DRN has been deployed as an interactive, web-based risk assessment tool that doctors can use to support early DRN screening and monitor patient evolution over time. Individuals identified as being at high risk of DRN could benefit from more frequent checkups and early interventions aimed at preventing or slowing down progressive neurodegeneration.
Because DRN is one of the first symptoms of nerve degeneration induced by diabetes, early detection could also signal the onset of nerve injury elsewhere in the body. Such damage can contribute to cognitive impairment, dementia, and peripheral neuropathy, which can cause loss of sensation and motor control in the hands, feet, and other extremities. A single eye test could therefore provide valuable insights into the overall health of the nervous system.
In addition, the proteins identified to be involved in DRN progression could be investigated as potential targets for the development of novel therapies. Furthermore, the AI-based tool could also prove valuable for the selection and stratification of participants in clinical trials evaluating neuroprotective strategies designed to prevent or delay nerve damage.
“Pro-DRN may help move diabetic eye care from detecting established damage toward earlier, molecularly informed risk stratification, so that closer monitoring and future neuroprotective interventions can be directed to the people most likely to benefit,” Wang and colleagues write.
The post AI-Powered Blood Test Detects Early Retinal Damage in Diabetes appeared first on Inside Precision Medicine.


![Statistical charts compiled from a large population allow brain abnormalities to be detected in new individuals. [Stevens INI]](https://www.genengnews.com/wp-content/uploads/2026/06/Julio-Villalon-press-release-image-1920x1080-1-1024x576.jpg)
